Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
September 24, 2024 16:20 ET | Kairos Pharma, Ltd.
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health...
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
January 30, 2024 09:45 ET | Kairos Pharma, Ltd.
LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...
Photodisinfection te
Photodisinfection technology could be a game-changer in fight against antimicrobial resistance
January 21, 2022 05:00 ET | Ondine Biomedical Inc.
Vancouver, Canada, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant...